Stryker Corp. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025, for Stryker Corp., a global leader in medical technologies. The company operates two primary segments: MedSurg and Neurotechnology and Orthopaedics. The reporting period includes the impact of the acquisition of Inari Medical, Inc. (Inari) in February 2025 and the divestiture of the Spinal Implants business in April 2025.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales ($ millions) | $6,022 | $5,422 | $11,888 | $10,665 |
| Gross Profit ($ millions) | $3,841 | $3,416 | $7,585 | $6,749 |
| Gross Margin (%) | 63.8% | 63.0% | 63.8% | 63.3% |
| Operating Income ($ millions) | $1,113 | $1,051 | $1,950 | $2,023 |
| Operating Margin (%) | 18.5% | 19.4% | 16.4% | 19.0% |
| Net Earnings ($ millions) | $884 | $825 | $1,538 | $1,613 |
| Diluted EPS ($) | $2.29 | $2.14 | $3.98 | $4.19 |
| Cash from Operations (YTD $ millions) | $1,361 | $837 | $1,361 | $837 |
| Total Debt ($ millions) | $16,580 | $13,597 | $16,580 | $13,597 |
| Cash & Equivalents ($ millions) | $2,375 | $3,652 | $2,375 | $3,652 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.1% in Q2 2025 and 11.5% YTD compared to 2024. Organic growth (excluding acquisitions/divestitures) was 10.2% in constant currency for both periods.
- Segment Performance: MedSurg and Neurotechnology sales grew 17.3% in Q2, driven by the Inari acquisition and volume increases across all businesses. Orthopaedics sales grew 2.0% in Q2, with volume increases offset by the divestiture of the Spinal Implants business.
- Profitability: While GAAP operating margin decreased to 18.5% in Q2 (from 19.4% in 2024) due to acquisition-related costs and amortization, adjusted operating margin increased to 25.7% (up 110 basis points). Adjusted net earnings per share rose 11.4% to $3.13.
- Acquisitions & Divestitures: The company spent $4.814 billion on acquisitions YTD, primarily for Inari. It also completed the sale of the Spinal Implants business, recognizing a tax benefit that lowered the effective tax rate to 13.0% in Q2.
- Debt Structure: Total debt increased to $16.58 billion as the company issued $3 billion in new senior unsecured notes in February 2025 to fund the Inari acquisition and refinance maturing debt.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong unit volume growth across MedSurg and Neurotechnology and most Orthopaedics businesses. The company expects segment mix to have an unfavorable impact on gross margin in the foreseeable future as the lower-margin MedSurg segment grows faster than Orthopaedics.
Risks and Contingencies:
- Macroeconomic Environment: New U.S. tariffs on goods from China and the EU announced in 2025 pose risks to product costs, supply chains, and demand.
- Legal and Regulatory: The company is investigating potential FCPA violations in foreign countries; the DOJ closed its inquiry in April 2025 without action, but other investigations remain open. The company maintains a $164 million accrual for product liability claims (e.g., Rejuvenate, ABG II hip stems).
- Taxation: Implementation of OECD Pillar Two global minimum tax rules in various jurisdictions may increase future tax expenses.
Investor Verification Checklist
- Verify the sustainability of the 10.2% organic sales growth rate given the impact of new tariffs on supply chains and pricing.
- Monitor the integration progress of Inari Medical and the realization of synergies to offset the $139 million share-based compensation charge and other acquisition costs.
- Assess the impact of the Spinal Implants divestiture on future Orthopaedics segment revenue and margin mix.
- Review the status of ongoing FCPA investigations and the potential for additional legal accruals beyond the current $164 million provision.
- Track the company's ability to manage interest expense on the increased debt load ($16.58 billion) amidst potential rate fluctuations.